Skip to main content

Table 1 General characteristic of the included studies. 1, need for transfusion; 2, total blood loss; 3, hidden blood loss; 4, intraoperative blood loss; 5, the occurrence of DVT; 6, the occurrence of hematoma

From: Comparative effectiveness and safety of tranexamic acid plus diluted epinephrine to control blood loss during total hip arthroplasty: a meta-analysis

Author

Country

Age (years, I/C)

No. of patients (n)

Interventions

Dose of intervention

Outcomes

Transfusion threshold

Follow-up

Gao F 2015

China

58.6 vs 61.7

53 vs 54

Topical TXA + topical DEP vs topical TXA

TXA (3 g), DEP (0.25 mg, 1:200000)

1, 2, 3, 4, 5, 6

Hb < 70 g/l

3 months

Jans O 2016

Denmark

67 vs 69

50 vs 50

Intravenous TXA + intravenous DEP vs intravenous TXA

TXA (1 g), DEP (0.05 μg kg−1 min−1)

2,3,

Hb < 80 g/l

At discharge

Liu JL 2018

China

50.0 vs 50.2 vs 51.8

65 vs 65 vs 65

Intravenous TXA + DEP vs intravenous TXA + topical DEP vs intravenous TXA

IV DEP (1 mg), IV TXA (10 mg/kg), topical DEP (0.25 mg, 1:200000)

1, 2, 3, 4, 5, 6

Hb < 70 g/l

2 weeks

Wang JW 2017

China

67 vs 69

45 vs 45

Topical TXA + topical DEP vs topical TXA

TXA (3 g), DEP (0.25 mg, 1:200000)

1, 2, 3, 4, 5, 6

Hb < 80 g/l

2 months

Zhang JK 2017

China

62.5 vs 63.1

21 vs 34

Topical TXA + topical DEP vs topical TXA

TXA (3 g), DEP (0.25 mg, 1:200000)

1, 2, 3, 4, 5, 6

Hb < 80 g/l

6 months

Zhang JZ 2017

China

59.8 vs 60.3 vs 58.6

52 vs 52 vs 52

Topical 1 g TXA + topical low dose DEP vs topical 1 g TXA + topical high dose DEP vs topical TXA

TXA (1 g), DEP (0.125 mg, 0.25 mg, 1:200000)

1, 2, 3, 4, 5

Hb < 70 g/l

3 months